PL1608647T3 - Pochodne 5-fenylotiazolu i ich zastosowanie jako inhibitorów kinazy PI3 - Google Patents
Pochodne 5-fenylotiazolu i ich zastosowanie jako inhibitorów kinazy PI3Info
- Publication number
- PL1608647T3 PL1608647T3 PL04717567T PL04717567T PL1608647T3 PL 1608647 T3 PL1608647 T3 PL 1608647T3 PL 04717567 T PL04717567 T PL 04717567T PL 04717567 T PL04717567 T PL 04717567T PL 1608647 T3 PL1608647 T3 PL 1608647T3
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- compounds
- phenylthiazole derivatives
- phenylthiazole
- derivatives
- Prior art date
Links
- ZLLOWHFKKIOINR-UHFFFAOYSA-N 5-phenyl-1,3-thiazole Chemical class S1C=NC=C1C1=CC=CC=C1 ZLLOWHFKKIOINR-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0305152.1A GB0305152D0 (en) | 2003-03-06 | 2003-03-06 | Organic compounds |
| EP04717567A EP1608647B1 (en) | 2003-03-06 | 2004-03-05 | 5-phenylthiazole derivatives and their use as p13 kinase inhibitors |
| PCT/EP2004/002285 WO2004078754A1 (en) | 2003-03-06 | 2004-03-05 | 5-phenylthiazole derivatives and their use as p13 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1608647T3 true PL1608647T3 (pl) | 2008-06-30 |
Family
ID=9954250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04717567T PL1608647T3 (pl) | 2003-03-06 | 2004-03-05 | Pochodne 5-fenylotiazolu i ich zastosowanie jako inhibitorów kinazy PI3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8017608B2 (pl) |
| EP (1) | EP1608647B1 (pl) |
| JP (1) | JP4382085B2 (pl) |
| CN (1) | CN100569770C (pl) |
| AT (1) | ATE383358T1 (pl) |
| AU (1) | AU2004218239B2 (pl) |
| BR (1) | BRPI0408068A (pl) |
| CA (1) | CA2517708A1 (pl) |
| DE (1) | DE602004011199T2 (pl) |
| ES (1) | ES2297393T3 (pl) |
| GB (1) | GB0305152D0 (pl) |
| MX (1) | MXPA05009468A (pl) |
| PL (1) | PL1608647T3 (pl) |
| PT (1) | PT1608647E (pl) |
| WO (1) | WO2004078754A1 (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| CA2607385C (en) * | 2005-05-24 | 2014-12-16 | Laboratoires Serono S.A. | Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases |
| DK1885716T3 (da) | 2005-05-24 | 2013-02-11 | Merck Serono Sa | Thiazolderivater og anvendelse deraf |
| AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| AU2006283846B2 (en) | 2005-08-26 | 2012-04-05 | Merck Serono Sa | Pyrazine derivatives and use as PI3K inhibitors |
| GB2431156A (en) * | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| AU2007206860A1 (en) * | 2006-01-23 | 2007-07-26 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| EP2016075A1 (en) * | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Thiazole derivatives and their use as anti-tumour agents |
| GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
| CN101528738A (zh) * | 2006-09-01 | 2009-09-09 | 沃泰克斯药物股份有限公司 | 可用作磷脂酰肌醇3-激酶抑制剂的5-（2-呋喃基）-1，3-噻唑衍生物 |
| GB0620059D0 (en) | 2006-10-10 | 2006-11-22 | Ucb Sa | Therapeutic agents |
| GB0620818D0 (en) | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
| NZ578229A (en) | 2007-02-22 | 2012-02-24 | Merck Serono Sa | Quinoxaline compounds and use thereof |
| AU2008287542C1 (en) | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2350067A2 (en) * | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| WO2010091996A1 (en) | 2009-02-12 | 2010-08-19 | Merck Serono S.A. | 2-morpholino-pyrido[3,2-d]pyrimidines |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| MX2012000178A (es) | 2009-07-02 | 2012-02-28 | Novartis Ag | 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k. |
| PH12012500901A1 (en) * | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| KR20130049766A (ko) | 2009-11-13 | 2013-05-14 | 메르크 세로노 에스. 에이. | 트리사이클릭 피라졸 아민 유도체 |
| EP2531194B1 (en) | 2010-02-03 | 2018-04-18 | Signal Pharmaceuticals, LLC | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| HRP20190128T1 (hr) * | 2011-05-04 | 2019-03-08 | Rhizen Pharmaceuticals S.A. | Novi spojevi kao modulatori protein kinaza |
| CA2843887A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| CN102633748A (zh) * | 2012-03-22 | 2012-08-15 | 盛世泰科生物医药技术(苏州)有限公司 | 2-甲酸乙酯-5-溴-1,3,4-噻二唑的合成方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法 |
| TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| AU2014254052B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| BR112015026292B1 (pt) | 2013-04-17 | 2022-04-12 | Signal Pharmaceuticals, Llc | Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro |
| US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| EP3003313A1 (en) | 2013-05-29 | 2016-04-13 | Signal Pharmaceuticals, LLC | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2017147526A1 (en) * | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| US10961236B2 (en) * | 2016-09-22 | 2021-03-30 | Astrazeneca Ab | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| KR20220035322A (ko) | 2019-03-21 | 2022-03-22 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Pi4-키나아제 억제제 및 이의 사용 방법 |
| WO2022017371A1 (zh) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60023926T2 (de) * | 1999-09-10 | 2006-07-20 | Merck & Co., Inc. | Tyrosin kinase inhibitoren |
| EP1857443B1 (en) | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| TWI314928B (en) * | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
-
2003
- 2003-03-06 GB GBGB0305152.1A patent/GB0305152D0/en not_active Ceased
-
2004
- 2004-03-05 CA CA002517708A patent/CA2517708A1/en not_active Abandoned
- 2004-03-05 JP JP2006500054A patent/JP4382085B2/ja not_active Expired - Lifetime
- 2004-03-05 AU AU2004218239A patent/AU2004218239B2/en not_active Ceased
- 2004-03-05 US US10/547,691 patent/US8017608B2/en not_active Expired - Fee Related
- 2004-03-05 PL PL04717567T patent/PL1608647T3/pl unknown
- 2004-03-05 MX MXPA05009468A patent/MXPA05009468A/es active IP Right Grant
- 2004-03-05 AT AT04717567T patent/ATE383358T1/de active
- 2004-03-05 EP EP04717567A patent/EP1608647B1/en not_active Expired - Lifetime
- 2004-03-05 DE DE602004011199T patent/DE602004011199T2/de not_active Expired - Lifetime
- 2004-03-05 BR BRPI0408068-8A patent/BRPI0408068A/pt not_active IP Right Cessation
- 2004-03-05 PT PT04717567T patent/PT1608647E/pt unknown
- 2004-03-05 ES ES04717567T patent/ES2297393T3/es not_active Expired - Lifetime
- 2004-03-05 CN CNB2004800117772A patent/CN100569770C/zh not_active Expired - Fee Related
- 2004-03-05 WO PCT/EP2004/002285 patent/WO2004078754A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004011199D1 (de) | 2008-02-21 |
| BRPI0408068A (pt) | 2006-02-14 |
| AU2004218239B2 (en) | 2007-02-22 |
| EP1608647A1 (en) | 2005-12-28 |
| CN1780832A (zh) | 2006-05-31 |
| MXPA05009468A (es) | 2006-02-13 |
| US8017608B2 (en) | 2011-09-13 |
| GB0305152D0 (en) | 2003-04-09 |
| PT1608647E (pt) | 2008-03-27 |
| ATE383358T1 (de) | 2008-01-15 |
| DE602004011199T2 (de) | 2009-01-02 |
| EP1608647B1 (en) | 2008-01-09 |
| AU2004218239A1 (en) | 2004-09-16 |
| JP2006515343A (ja) | 2006-05-25 |
| JP4382085B2 (ja) | 2009-12-09 |
| US20060148822A1 (en) | 2006-07-06 |
| CA2517708A1 (en) | 2004-09-16 |
| CN100569770C (zh) | 2009-12-16 |
| WO2004078754A1 (en) | 2004-09-16 |
| ES2297393T3 (es) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1608647T3 (pl) | Pochodne 5-fenylotiazolu i ich zastosowanie jako inhibitorów kinazy PI3 | |
| MY156407A (en) | 5-phenylthiazole derivatives and use as p13 kinase inhibitors | |
| TNSN05278A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
| TNSN06064A1 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
| MXPA05010712A (es) | Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
| SE0300480D0 (sv) | Novel compounds | |
| SE0202539D0 (sv) | Compounds | |
| TW200801003A (en) | Novel compounds | |
| SE0200920D0 (sv) | Novel compounds | |
| TW200514776A (en) | Aminotriazole compounds useful as inhibitors of protein kinases | |
| TW200613243A (en) | Novel compounds | |
| TNSN08020A1 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
| SE0302139D0 (sv) | Novel compounds | |
| TW200604197A (en) | New compounds | |
| TW200738659A (en) | Novel compounds | |
| TW200639156A (en) | New compounds | |
| SE0401763D0 (sv) | Compounds | |
| NO20053809L (no) | Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav | |
| EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
| SE0202693D0 (sv) | Compounds | |
| SE0302755D0 (sv) | Novel compounds | |
| SE0202692D0 (sv) | Compounds | |
| WO2007068473A3 (en) | Organic compounds | |
| SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them |